Search results
Showing 601 to 615 of 711 results for medication
NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds
Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management (CG84)
This guideline covers diagnosing, managing and referring infants and young children younger than 5 years who present with acute diarrhoea (lasting up to 14 days) with or without vomiting. It aims to improve the diagnosis and management of infective gastroenteritis and appropriate escalation of care.
AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis (MIB46)
NICE has developed a medtech innovation briefing (MIB) on the AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis
and aspirated saliva (up to 2 litres/day) may be infected as a result. Medications are not given orally, and patients may be distressed...
Standards framework for shared-decision-making support tools, including patient decision aids (ECD8)
This document describes the framework for setting out a series of standards to support people using patient decision aids (PDAs) in assessing the usefulness and quality of a PDA. It will also be useful to those developing PDAs in enabling them to undertake a self-assessment of the quality of their tools and processes
NICE has developed a medtech innovation briefing (MIB) on The Insides System for managing intestinal failure .
Evidence-based recommendations on caplacizumab (Cablivi) with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura in adults, and in young people aged 12 years and over who weigh at least 40 kg.
Apremilast for treating moderate to severe plaque psoriasis (TA419)
Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.
This quality standard covers diagnosing and managing irritable bowel syndrome in adults. It describes high-quality care in priority areas for improvement.
This guideline covers decision-making in people 16 years and over who may lack capacity now or in the future. It aims to help health and social care practitioners support people to make their own decisions where they have the capacity to do so. It also helps practitioners to keep people who lack capacity at the centre of the decision-making process.
NICE has developed a medtech innovation briefing (MIB) on point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease .
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)
Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.
NICE has developed a medtech innovation briefing (MIB) on the Somatom Definition Edge CT scanner for imaging coronary artery disease in adults in whom imaging is difficult .
Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making